Unknown

Dataset Information

0

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.


ABSTRACT: Introduction:Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral cyclophosphamide and an accelerated prednisone taper. Methods:Patients were included in this retrospective study if they had newly diagnosed or relapsing ANCA vasculitis with a Birmingham Vasculitis Activity Score for Wegener Granulomatosis (BVAS-WG) ?3 and received a standardized remission induction regimen. The primary outcome was complete remission, defined as a BVAS-WG of 0 and a prednisone dose of ?7.5 mg/d. Results:We identified 129 patients who met the inclusion criteria, 31% of whom also received plasma exchange (PLEX) for rapidly progressive glomerulonephritis (RPGN) or diffuse alveolar hemorrhage. Seventy percent of patients had myeloperoxidase (MPO)-ANCA and 9% had relapsing disease. Median time to complete remission was 4 months (interquartile range [IQR] 3.9-4.4), and by 5 months 84% of patients were in complete remission. Prednisone was tapered to discontinuation as tolerated, such that the median prednisone dose at 8 months was 0 mg/d (IQR 0-2.5). In patients with RPGN, proteinase 3-ANCA was associated with a greater increase in eGFR at 6 months compared with MPO-ANCA (16 vs. 5.6 ml/min per 1.73m2; P = 0.028). During the year following remission, 1 major relapse occurred over 122 patient-years. Serious infections occurred more frequently in patients receiving PLEX and were associated with increasing age and diffuse alveolar hemorrhage. Four deaths occurred, 3 of which were associated with serious infections. Conclusion:Combination therapy was efficacious, allowed for rapid tapering of high-dose glucocorticoids and was well tolerated.

SUBMITTER: Cortazar FB 

PROVIDER: S-EPMC5932132 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

Cortazar Frank B FB   Muhsin Saif A SA   Pendergraft William F WF   Wallace Zachary S ZS   Dunbar Colleen C   Laliberte Karen K   Niles John L JL  

Kidney international reports 20171114 2


<h4>Introduction</h4>Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral cyclophosphamide and an accelerated prednisone taper.<h4>Methods</h4>Patients were included in this retrospective study if they had newly diagnosed or relapsing ANCA vasculitis with a Birmingham  ...[more]

Similar Datasets

| S-EPMC3137658 | biostudies-literature
| S-EPMC4378104 | biostudies-literature
| S-EPMC5953195 | biostudies-literature
| S-EPMC7612177 | biostudies-literature